Squamous Cell Carcinoma of the Skin Clinical Trial
Official title:
Dose Escalation Study of Neoadjuvant Intratumoral PH-762 for Cutaneous Squamous Cell Carcinoma, Melanoma, or Merkel Cell Carcinoma
The goal of this clinical trial is to evaluate the safety and tolerability of intratumoral injections of PH-762 in squamous cell carcinoma, melanoma, or Merkel cell carcinomas of the skin, to understand what the body does to the PH-762, and to observe how the tumor responds to the drug. Participants will receive four injections of PH-762 at weekly intervals, into a single tumor, followed by surgical removal of the tumor approximately two weeks later.
PH-762 is a potent RNAi molecule targeting PD-1. PH-762 can inhibit the immune checkpoint PD-1 in the tumor and thereby impede tumor growth. As a preoperative therapy, it may decrease the lesion size and has the potential to improve surgical morbidity. Intratumoral immunotherapy aims to use the tumor as a 'self-vaccine'. The local immune stimulation can induce robust priming of an anti-tumor immune response while generating systemic (abscopal) tumor responses, mediated by properly activated anti-tumor immune cells in the circulation. Local delivery of immunotherapy is expected to minimize systemic exposure and off-target toxicities. This is a non-comparative study of neoadjuvant monotherapy using PD-1 targeting self-delivering RNAi (PH-762) in adult subjects with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. The study treatment consists of four intratumoral injections of PH-762 at weekly intervals, into a single tumor lesion. Excision of the tumor will occur approximately two weeks following the fourth dose of IT PH-762, and the subjects will be followed for an additional 11 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03291002 -
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
|
Phase 1 | |
| Active, not recruiting |
NCT06327971 -
Enhanced Outcome Prediction in Cutaneous Squamous Cell Carcinoma Using Deep-learning and Computational Histopathology
|
||
| Not yet recruiting |
NCT03621462 -
Elucid Labs AIDA™ - Labelled Image Acquisition Protocol
|
N/A | |
| Not yet recruiting |
NCT04480645 -
CivaDerm(TM) Surface Therapy Pilot Study
|
Early Phase 1 | |
| Recruiting |
NCT03370861 -
How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
|
||
| Completed |
NCT02347813 -
Preventing Squamous Cell Skin Cancer
|
Phase 2 | |
| Terminated |
NCT01984892 -
Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
|
Phase 2 | |
| Completed |
NCT00563290 -
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia
|
Phase 2 | |
| Recruiting |
NCT04204837 -
Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin
|
Phase 2 | |
| Active, not recruiting |
NCT03894618 -
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
| Terminated |
NCT01823679 -
Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin
|
Phase 2 | |
| Completed |
NCT00126555 -
Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
|
Phase 2 | |
| Completed |
NCT00089180 -
T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant
|
Phase 2 | |
| Not yet recruiting |
NCT05246228 -
Immune System Modulation and Outcome in High-risk cSCC Treated With Surgery and Radiotherapy
|
||
| Recruiting |
NCT05886140 -
Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin
|
N/A | |
| Completed |
NCT02324608 -
Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer
|
N/A | |
| Recruiting |
NCT02717936 -
Investigation of Desmoplastic Squamous Cell Carcinoma
|
N/A | |
| Recruiting |
NCT05482880 -
Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region
|
||
| Withdrawn |
NCT01465815 -
Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05490485 -
Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
|
Phase 2 |